HitGen Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Li Jin

Chief Executive Officer (CEO)

CN¥3.3m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	20.5%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Mar 07

CEO

Li Jin (60 yo)

no data

Permanencia

CN¥3,335,800

Compensación

Mr. Li Jin serves as Chairman of the Board and General Manager at HitGen Inc.

HitGen Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

HitGen Inc., Annual General Meeting, May 22, 2024

Recent updates

HitGen Inc., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)

HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released

New minor risk - Share price stability

Consensus EPS estimates fall by 41%

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)

HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023

HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research

Price target increased by 22% to CN¥23.00

First quarter 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.02 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Third quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.06 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥28.50

Full year 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.02 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.02 in 1Q 2020)

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.33 in FY 2019)

Revenue behind estimates

HitGen and UPPTHERA Entera Into Drug Discovery Research Collaboration

New 90-day high: CN¥40.13

New 90-day low: CN¥29.19

HitGen Announces License Agreement With Merck & Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of Novel Class of Drugs

Cedilla Therapeutics, Inc. and HitGen Inc. Announces Research Collaboration Focused on Dna-Encoded Library Based Drug Discovery

HitGen Licenses its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

New 90-day low: CN¥31.33

HitGen Inc. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥36.33

HitGen Inc. (SHSE:688222) agreed to acquire Vernalis (R&D) Limited from Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) for $25 million.

New 90-day low: CN¥37.61

New 90-day low - CN¥38.20

First half earnings released

New 90-day low - CN¥40.30

HitGen Inc. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Permanencia

Compensación